AstraZeneca (AZN), Ardelyx Enter NH3 Inhibitor Licensing Program

Go back to AstraZeneca (AZN), Ardelyx Enter NH3 Inhibitor Licensing Program

From AstraZeneca Website

AstraZeneca and Ardelyx announce worldwide licensing deal for NHE3 inhibitor programme for complications of renal disease, including diabetes-induced renal disease